Report
(Sponsored) Oncodesign Precision Medicine - OPM-101 Ph1 data prompt further clinical development
Yesterday, OPM announced successful completion of its Ph1 study with healthy volunteers for its RIPK2 inhibitor ‘OPM-101'. Data indicates safety, rapid onset of action, and strong/sustained target engagement.Ph1b/2a expected to commence by year-end with indication to be determined (prioritization of immune checkpoint inhibitor-induced colitis not reiterated) and study design to be finalized. Hence, we are somewhat left in the dark regarding next steps and therefore look forward to an update regarding the asset's further development.We consider the data to be promising, especially with the high dose, prompting further clinical development of OPM-101. Due to the lack of clinical (especially efficacy)
Underlying
Oncodesign Precision Medicine
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.